WallStSmart

Aquestive Therapeutics Inc (AQST)vsTakeda Pharmaceutical Co Ltd ADR (TAK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Takeda Pharmaceutical Co Ltd ADR generates 9609900% more annual revenue ($4.69T vs $48.84M). TAK leads profitability with a 0.9% profit margin vs -162.3%. TAK earns a higher WallStSmart Score of 54/100 (C-).

AQST

Avoid

18

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 4.0Quality: 6.5
Piotroski: 2/9Altman Z: -4.23

TAK

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 5.5Value: 5.7Quality: 4.5
Piotroski: 3/9Altman Z: 1.05
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AQSTSignificantly Overvalued (-52.8%)

Margin of Safety

-52.8%

Fair Value

$2.50

Current Price

$3.46

$0.96 premium

UndervaluedFair: $2.50Overvalued

Intrinsic value data unavailable for TAK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AQST1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.1110/10

Conservative balance sheet, low leverage

TAK4 strengths · Avg: 9.8/10
PEG RatioValuation
0.4810/10

Growing faster than its price suggests

Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Free Cash FlowQuality
$212.65B10/10

Generating 212.6B in free cash flow

Market CapQuality
$68.40B9/10

Large-cap with strong market position

Areas to Watch

AQST4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$491.44M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

TAK4 concerns · Avg: 2.8/10
Return on EquityProfitability
5.2%3/10

ROE of 5.2% — below average capital efficiency

Profit MarginProfitability
0.9%3/10

0.9% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
305.9x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : AQST

The strongest argument for AQST centers on Debt/Equity.

Bull Case : TAK

The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.48 suggests the stock is reasonably priced for its growth.

Bear Case : AQST

The primary concerns for AQST are EPS Growth, Market Cap, Return on Equity.

Bear Case : TAK

The primary concerns for TAK are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 305.9x leaves little room for execution misses. Thin 0.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

AQST profiles as a turnaround stock while TAK is a value play — different risk/reward profiles.

AQST carries more volatility with a beta of 1.50 — expect wider price swings.

TAK is growing revenue faster at 6.7% — sustainability is the question.

TAK generates stronger free cash flow (212.6B), providing more financial flexibility.

Bottom Line

TAK scores higher overall (54/100 vs 18/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aquestive Therapeutics Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.

Takeda Pharmaceutical Co Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.

Want to dig deeper into these stocks?